初发急性ST段抬高心肌梗死患者预后的影响因素分析

目的:研究初发急性ST段抬高心肌梗死患者预后的影响因素。方法:选取我院2010年收治的发病24小时内初发急性ST段抬高心肌梗死(ST-segment elevation myocardial infarction,STEMI)258例,收集患者病史、化验检查、心脏彩超、冠状动脉造影结果等住院资料,并随访主要心血管事件,通过相关分析求出对预后有统计学意义的因素,再分别通过Logistic回归及Cox回归分析急性心肌梗死患者近期及远期预后的影响因素。结果:AMI患者住院死亡率6.2%(16/258例),影响住院死亡率因素为PCI治疗(r=-0.253,P=0.000,OR=0.318,95%CI:0.101-0.997)、血糖(Glu)(r=0.24,P=0.01,OR=1.136,95%CI:1.020-1.265)两个因素;平均随访7.6±3.8月,总终点事件10.3%(25/242例),心源性死亡患者6例(2.5%);经Cox回归分析与远期死亡相关的因素是高敏C反应蛋白(Hs CRP)(r=0.182,P=0.008,OR=1.223,95%CI:1.065-1.403)。结论:急性心肌梗死预后受多种因素影响,影响住院死亡率的因素为PCI治疗及血糖,影响远期死亡的因素是Hs CRP。     

老年重症肺炎接受机械通气患者血清超敏C反应蛋白与短期预后的关系

目的:探讨老年重症肺炎接受机械通气患者血清超敏C反应蛋白(hs-CRP)与短期预后的关系。方法:将97例老年重症肺炎接受机械通气治疗的患者按照入院第28h的预后分为死亡组(n=34例)和存活组(n=63例),同时按照肺炎严重指数(PSI)和CURB-65评分将患者分为Ⅳ级组(90~130分)(n=29例)和V级组(130分)(n=68例);CURB-65评分2分组(n=31例)和CURB-65评分3~5分组(n=66例);比较各组患者相关临床指标、入院第1 d、3 d、7 d的血清hs-CRP水平的差异,分析血清hs-CRP水平与近期预后的关系。结果:死亡组与存活组患者在机械通气时间、CURB-65评分、PSI、血清白蛋白(ALB)、降钙素原(PCT)、血乳酸(Lac)方面存在统计学差异(P0.05);死亡组患者入院第1 d、3 d、7 d的血清hs-CRP水平显著高于死亡组(P0.05);PSI中V级组,CURB-65评分3~5分组中入院第1 d、3 d、7 d的血清hs-CRP水平亦高于Ⅳ级组和CURB-65评分2分组。血清hs-CRP水平是患者近期死亡的独立危险因素。入院后第1 d、3 d、7 d的血清hs-CRP水平患者死亡的ROCAUC分别为0.844、0.914、0.772,最佳诊断截点分别为51.76 mg/L、92.56 mg/L及49.38 mg/L。结论:血清hs-CRP水平是老年重症肺炎接受机械通气患者近期死亡的独立危险因素,动态检测血清hs-CRP变化对评估患者预后具有一定的临床意义。     

血浆脑钠肽对不同年龄急性冠脉综合征患者介入治疗术后 临床预后的意义

目的:探讨并比较血浆脑钠肽(BNP)对不同年龄组急性冠脉综合征(ACS)患者经皮冠脉介入(PCI)术后临床主要不良心脏事件(MACE)的预测价值。方法:回顾分析2007年12月至2010年3月因ACS在我院行PCI的患者,分为≥60岁和<60岁两组,入院常规检验BNP,随访住院期间及出院后6个月内MACE(包括死亡、心源性休克、再发心绞痛、非致命性再次心肌梗死、非致命性心力衰竭、心律失常、靶血管血运重建、再次入院复合终点)的发生情况。结果:随访269例≥60岁患者,失访7例(2.6%),118例<60岁患者,失访3例(2.5%),。262例≥60岁患者的年龄与BNP水平显著正相关(r=0.368,P<0.01),而115例<60岁患者无显著相关性(r=-0.014,P>0.05)。年龄≥60岁患者BNP水平与<60岁患者比较,差异显著(P<0.01),年龄≥60岁患者MACE与<60岁患者比较,差异显著(P<0.01),两组患者BNP水平与LVEF呈显著负相关(P均<0.01)。多因素logistic回归分析显示:BNP可独立预测两组患者住院期间及出院后6个月内MACE(≥60岁OR=4.369 P<0.01;<60岁OR=7.773 P<0.01)发生率。两组患者BNP水平对MACE预测的ROC曲线结果比较,差异无统计学意义(P>0.05)。结论:不同年龄患者BNP水平及MACE发生率存在差异,但年龄并不影响BNP对ACS患者临床预后的预测价值。     

基于Tilburg衰弱评估量表评价的老年慢性心力衰竭合并衰弱的危险因素探讨及其对患者生活质量和预后的影响

摘要 目的：基于Tilburg衰弱评估量表评价老年慢性心力衰竭（CHF）的衰弱状况，分析影响衰弱的危险因素，并探讨其对患者生活质量和预后的影响。方法：选取2020年3月～2022年3月我院收治的102例老年CHF患者，根据Tilburg衰弱评估量表分为衰弱组与非衰弱组。收集患者基线资料，采用明尼苏达州心力衰竭生活质量问卷（MLHFQ）评分评估患者的生活质量，采用多因素Logistic回归分析老年CHF患者合并衰弱的危险因素，Spearman相关性分析衰弱组Tilburg衰弱评估量表评分与MLHFQ评分的相关性，比较两组患者生活质量和90 d非计划再入院率、死亡率。结果：102例老年CHF患者合并衰弱的发生率为53.92％（55/102）。多因素Logistic回归分析显示：体质指数（BMI）降低、NYHA心功能分级Ⅲ～Ⅳ级、合并疾病数量增加、血红蛋白（Hb）降低、红细胞分布宽度（RDW）升高、白蛋白（Alb）降低、N末端B型脑钠肽前体（NT-ProBNP）升高为老年CHF患者合并衰弱的独立危险因素（P＜0.05）。衰弱组MLHFQ身体领域、情绪领域、其他领域评分高于非衰弱组（P＜0.05）。Spearman相关性分析显示，老年CHF患者合并衰弱患者Tilburg衰弱评估量表评分与MLHFQ身体领域、情绪领域、其他领域评分呈正相关（rs=0.505、0.424、0.526，P均＜0.001）。随访90 d，衰弱组非计划再入院率高于非衰弱组（P＜0.05）。结论：老年CHF患者衰弱状况发生率较高，BMI、NYHA心功能分级、合并疾病数量、Hb、RDW、Alb、NT-ProBNP为老年CHF患者合并衰弱的影响因素，衰弱可导致患者生活质量下降和预后不良。Tilburg衰弱评估量表能快速评价老年CHF患者合并衰弱状况，有助于指导临床及时采取干预措施改善患者生活质量和预后。     

药物洗脱支架植入术与冠状动脉旁路移植术治疗冠心病多支病变伴糖尿病患者的临床效果分析

目的:比较药物洗脱支架(DES)植入术及冠状动脉旁路移植术(CABG)治疗冠心病多支病变伴糖尿病患者的近期及远期临床疗效。方法:回顾性分析2014年1月~2016年10月在哈尔滨医科大学附属第一医院经冠状动脉造影证实为多支血管病变并伴有糖尿病的患者186例,根据血运重建方式的不同分为DES组及CABG组,随访50.5±14.3个月,观察两组患者住院期间及随访期主要不良心脑血管事件(包括非致死心肌梗死、脑卒中、再次血运重建、全因死亡)的发生情况。结果:在所有入选患者中,DES组有更多双支病变(P0.05),CABG组三支病变较多(P0.05),两组在完全血运重建方面无显著性差异(P0.05)。住院期间,CABG组死亡2例(2.3%),DES组死亡1例(1.0%),死亡率比较无统计学意义(P0.05)。两组均未出现非致死性心肌梗死、脑卒中、再次血运重建。出院后对186例入选患者随访,其中失访11例(DES组5例,CABG组6例)。随访期间CABG组发生非致死性心肌梗死1例(1.3%)、脑卒中6例(7.5%)、全因死亡10例(12.5%),DES组发生非致死性心肌梗死5例(5.3%)、脑卒中3例(3.2%)、全因死亡9例(9.5%),两组间比较差异无统计学意义(P0.05);而CABG组再次血运重建2例(2.5%),DES组15例(15.8%),两组比较差异具有统计学意义(P0.01)。结论:行DES置入术或CABG术治疗冠心病多支病变伴糖尿病患者,住院期间主要心脑血管不良事件发生率、远期非致死性心肌梗死、脑卒中、全因死亡发生情况均无显著性差异,但DES组再次血运重建率明显升高,可能与糖尿病患者较高的再狭窄率有关。     

血清PCT、presepsin和Gas6对老年慢性心力衰竭合并肺部感染患者病情及预后的评估价值

摘要 目的：探讨血清降钙素原（PCT）、白细胞分化抗原14亚型（presepsin）联合生长停滞特异性基因产物6（Gas6）对老年慢性心力衰竭（CHF）患者合并肺部感染患者病情及预后的评估价值。方法：412例老年CHF患者根据有无合并肺部感染分为肺部感染组（n=176）和无肺部感染组（n=236）,另选取同期体检健康的40例健康体检者作为健康对照组,比较三组血清PCT、presepsin、Gas6水平。统计住院28 d内老年CHF合并肺部感染患者的预后情况,根据预后不同分为死亡组（n=37）和生存组（n=139）,多因素Logistic回归模型分析老年CHF合并肺部感染患者死亡的危险因素。采用受试者工作特征（ROC）曲线分析血清PCT、presepsin联合Gas6对老年CHF合并肺部感染患者死亡的预测价值。结果：肺部感染组和无肺部感染组血清PCT、presepsin、Gas6水平均高于健康对照组,且肺部感染组高于无肺部感染组（P＜0.05）。多因素Logistic回归分析显示,年龄偏高、心功能分级Ⅳ级、PCT升高、presepsin升高、Gas6升高均是导致老年CHF合并肺部感染患者死亡的独立危险因素（P＜0.05）。ROC结果显示,血清PCT、presepsin、Gas6单独及联合检测对预测老年CHF合并肺部感染患者死亡风险的AUC分别为0.663、0.731、0.751、0.855,三指标联合检测的预测效能优于各指标单独检测。结论：血清PCT、presepsin及Gas6水平在老年CHF合并肺部感染患者中升高,且是短期预后不良的独立危险因素,检测PCT、presepsin及Gas6水平对老年CHF合并肺部感染患者病情及预后具有一定评估价值。     

抗HP治疗对急性冠脉综合征合并HP感染患者血清炎性标记物及再发心肌缺血事件的影响

目的:探讨抗幽门螺杆菌(HP)治疗对急性冠脉综合征(ACS)合并HP感染患者炎性标记物及再发心肌缺血事件的影响。方法:选取2016年10月到2018年10月期间我院收治的ACS患者90例,随机分为对照组(n=45,常规治疗)和观察组(n=45,常规治疗+抗HP治疗)。观察两组患者的临床疗效,比较HP根除率、血清炎性标记物[C反应蛋白(CRP)、白细胞介素-6(IL-6)、可溶性细胞间粘附分子-1(sICAM-1)]水平,记录再发心肌缺血事件和不良反应发生情况。结果:观察组的总有效率和HP根除率均高于对照组(P0.05)。两组患者经治疗后血清CRP、IL-6、sICAM-1水平均较治疗前有所改善(P0.05),且观察组的改善效果优于对照组(P0.05)。观察组患者再发心肌缺血事件的总发生率低于对照组(P0.05)。两组患者的不良反应发生率比较无明显差异(P0.05)。结论:ACS合并HP感染患者采取抗HP治疗可更好地缓解患者体内的炎症反应,降低再发心肌缺血事件发生率的同时还不会增加不良反应发生风险。     

磺达肝癸钠在65岁以上急性心肌梗死患者中的临床应用研究

目的:对比磺达肝癸钠(商品名:安卓,葛兰素史克)与那曲肝素(商品名:速碧林,葛兰素史克)在65岁以上急性心肌梗死患者中的有效性和安全性.方法:入选急性心肌梗死住院患者84例随机分为实验组(安卓2.5 mg每天一次皮下注射7天,n=45)和对照组(速碧林,5000 IU(0.4 ML),每天2次皮下注射7天,n=39),随访1个月.对比实验组和对照组抗凝效果.比较两组住院期间及治疗1个月内心源性死亡发生率及出血发生率.结果:(1)实验组与对照组相比,在治疗1周,心源性死亡发生率显著降低,两者差异有统计学意义(P＜0.05).1个月时,两组比较无统计学意义(P＞0.05)(2)出血发生率,实验组较对照组显著降低,轻中度出血发生率有统计学意义(P＜0.05).严重出血发生率有统计学意义(P＜0.05).结论:在急性心肌梗死患者治疗中,磺达肝癸钠与那曲肝素相比更安全有效.     

不同类型的急性冠脉综合征患者血清热休克蛋白60浓度比较研究

目的:了解急性冠脉综合征(ACS)发作时热休克蛋白60(HSP60)及其抗体的血清浓度变化情况。方法:测定各类不稳定性心绞痛(UA,n=32)、S-T段抬高性心肌梗死(STEMI,n=16)和非ST段抬高性心肌梗死(NSTEMI,n=8)和健康对照(n=38)血清HSP60及其抗体的浓度并作统计学比较。结果:各型ACS患者血清HSP60和抗体水平均显著高于对照组(P<0.05),且STEMI患者血清HSP和抗体水平显著高于UA和NSTEMI患者(P<0.05)。结论:测定患者血清HSP60水平可以用于协助ACS诊断和疾病进程监测。     

红细胞分布宽度对NSTE-ACS患者行PCI术植入DES长期生存率的影响

本研究旨在评价红细胞分布宽度(red blood cell distribution width,RDW)对植入药物洗脱支架(drugeluting stents,DES)的非ST段抬高急性冠脉综合征患者(non-ST elevation myocardial infarction,NSTE-ACS)远期预后的影响。研究纳入南方医科大学珠江医院2013年2月1日至2014年1月31日在心内科行经皮冠状动脉介入术(percutaneous coronary intervention,PCI)并植入DES的NSTE-ACS患者共181名,其中男性136例,女性45例,按照入院时的RDW的中位数分为2组;RDW≥13.3%为高RDW组,RDW13.3%为低RDW组。收集患者的相关临床资料采用门诊、电话等形式进行随访,比较两组患者之间长期生存率。纳入符合条件的患者181例,完成随访177例(97.8%),随访时间(14.67±5.78)月。2组患者基线资料中RDW血小板,受体阻滞剂(BETA BLOCK)比较,差异有统计学意义。高、低RDW两组患者随访结果显示,高RDW组全因死亡率及主要心脏不良事件(major adverse cardiac events(MACE))发生率与低RDW组比较有统计学差异,随访期间内靶血管再次血运重建的概率两组有统计学差异。Cox多元回归分析显示RDW升高是全因死亡和MACE发生率的预测因子,高RDW和LVEF≤40%与病死率相关。Kaplan-Meier曲线显示两组间全因死亡率和MACE事件发生率差异有统计学意义(Log-rank p=0.025,p=0.005)。本研究结果显示RDW升高是植入药物洗脱支架的NSTE-ACS患者不良临床预后的独立预测因子。     

Similar Cardiovascular Outcomes Between Insulin Detemir and Insulin Glargine In Type 2 Diabetic Patients With Extremely Atherosclerotic Cardiovascular Disease Risks

Objective: The cardiovascular outcomes of insulin detemir in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) are unclear. The aim of our real-life cohort study was to evaluate the cardiovascular outcomes of insulin detemir (IDet) versus insulin glargine (IGlar) in T2DM patients after ACS or AIS.Methods: A retrospective cohort study was conducted between June 1, 2005, and December 31, 2013, utilizing the Taiwan National Health Insurance Research Database. A total of 3,129 ACS or AIS patients were eligible for the analysis. Clinical outcomes were evaluated by comparing 1,043 subjects receiving IDet with 2,086 propensity score-matched subjects who received IGlar. The primary composite outcome included cardiovascular (CV) death, nonfatal myocardial infarction (MI) and nonfatal stroke.Results: The primary composite outcome occurred in 322 patients (30.9%) in the IDet group and 604 patients (29.0%) in the IGlar group (hazard ratio [HR], 1.12; 95% confidence interval [CI], 0.95 to 1.32) with a mean follow-up of 2.4 years. No significant differences were observed for CV death (HR, 1.09; 95% CI, 0.86 to 1.38), nonfatal MI (HR, 0.88; 95% CI, 0.66 to 1.19), and nonfatal stroke (HR, 1.15; 95% CI, 0.97 to 1.35). There were similar risks of all-cause mortality, hospitalization for heart failure and revascularization between the IDet group and the IGlar group (P = .647, .115, and .390 respectively).Conclusion: Compared with IGlar, in T2DM patients after ACS or AIS, IDet was not associated with increased risks of CV death, nonfatal MI, or nonfatal stroke.Abbreviations: ACS = acute coronary syndrome; AIS = acute ischemic stroke; ASCVD = atherosclerotic cardiovascular disease; CI = confidence interval; CV = cardiovascular; DKA = diabetic ketoacidosis; HHF = hospitalization for heart failure; HHS = hyperosmolar hyperglycemic state; HR = hazard ratio; IDet = insulin detemir; IGlar = insulin glargine; MI = myocardial infarction; NHIRD = National Health Insurance Research Database; PCI = percutaneous coronary intervention; PSM = propensity score matching; T2DM = type 2 diabetes mellitus     

老年急性心肌梗死并心源性休克冠状动脉介入治疗的临床效果分析

目的:对比分析介入治疗和保守治疗对急性心梗合并心源性休克的老年患者的治疗效果。方法:回顾性分析急性心肌梗死并心源性休克患者,共入选230例,按照医生评估进行分组治疗,分为介入治疗组和非介入治疗组,介入组患者120例,接受冠脉介入治疗;非介入组患者110例,接受非介入治疗。对比分析危险因素以及治疗效果。结果:介入组中心肌梗死病史及心衰病史患者明显高于非介入组(24.2%vs 20%P<0.05;25%vs 17.3%,P<0.05),经皮冠状动脉介入治疗与非介入治疗相比能显著降低急性心梗合并心源性休克的老年患者住院病死率(40.8%vs 71.8%,P<0.05),非介入治疗组心律失常发生率高于介入治疗组(26.7%vs 21.8%,P<0.05),同时非介入治疗组肺部感染及肾衰的发病率较高(11.8%vs 5.8%P<0.05;8.2%vs 2.0%,P<0.05)。结论:针对急性心梗合并心源性休克的老年患者制定治疗方案时,虽然介入治疗存在更多的并发症,但是可以显著改善患者预后。     

Procedural and long-term outcome of primary percutaneous coronary intervention in octogenarians

Background/objectives. To investigate the procedural and long-term outcome of primary percutaneous coronary intervention (PCI) in octogenarians with an acute myocardial infarction. Methods. We performed a retrospective analysis of all consecutive octogenarian patients (n=98) with an acute myocardial infarction treated with primary PCI in the Catharina Hospital in the year 2006. We compared procedural results and outcome with a matched control group composed of non-octogenarians undergoing primary PCI. Follow-up period was one year. Results. The initial success rate of PCI was similar in the two groups but short-term mortality was higher among the elderly patients: 30-day mortality 26.3 vs. 9.6%. Age-adjusted mortality between 30 days and one year was comparable in the two groups and similar to natural survival in the Netherlands. Octogenarians were less likely to have a normal left ventricular function during follow-up (48.3 vs. 66.7%). New York Heart Association (NYHA) class and recurrence rate of myocardial infarction was higher among octogenarians. Conclusion. Technical success rate during primary PCI was as good for octogenarians as in younger patients, but 30-day mortality, though acceptable, was higher among the elderly. After 30 days, age-adjusted mortality was comparable in both groups. (Neth Heart J 2010;18:129-34.)     

Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes

Abstract

Purpose: The aim of our study was to analyse the long-term prognostic value of soluble urokinase plasminogen activator receptor (suPAR) in the setting of an acute coronary syndrome (ACS).

Methods: We included 340 patients with an ACS who underwent coronary angiography and plasma suPAR concentration was measured. Patients were classified into low suPAR concentrations (<2.6?ng/mL) and high suPAR concentrations (≥2.6?ng/mL) and long-term events were evaluated. suPAR prognostic value was assessed beyond a clinical model that included age, GRACE score, estimated glomerular filtration rate, cardiac troponin-I peak and left ventricular ejection fraction <40%.

Results: Higher suPAR concentrations were associated with an increased prevalence of cardiovascular risk factors. After multivariate adjustment, suPAR ≥2.6?ng/mL were independently associated with an increased risk of all-cause death (HR 2.3; 95%CI 1.2–4.4; p?=?.017), major adverse cardiovascular events (MACE) (HR 1.7; 95%CI 1.1–2.5; p?=?.020) and heart failure (HR 4.1; 95%CI 1.3–12.6; p?=?.015), but not with myocardial infarction. For long-term all-cause death significant improvement of reclassification and discrimination were seen after addition of suPAR to a clinical model.

Conclusions: In the setting of an ACS, suPAR is associated with long-term all-cause death, heart failure and MACE, and provides incremental prognostic value beyond traditional risks factors.     

经皮冠脉介入手术时机的选择对急性心肌梗死患者左室重构及心功能的影响

目的:探讨手术时机的选择对急性心肌梗死患者行经皮冠脉介入手术后左室重构及心功能的影响。方法:选择2014年10月-2015年10月在我院接受经皮冠脉介入手术治疗的97例急性心肌梗死患者为研究对象,根据手术时间不同将患者分为急诊手术组(49例)和择期手术组(48例)。观察并比较两组患者手术前后平均二尖瓣压力差(mMPG)、肺动脉平均压(mPAP)、左室舒张末径(LVDEd)、左室收缩末径(LVSEd)、左房内径(LAd)以及半年内心衰再住院率。结果:手术前,两组患者心功能及血流动力学各指标比较,差异均无统计学意义(P0.05);手术后,两组患者LVDEd,LVSEd及LAd均低于手术前,且急诊手术组患者LVDEd,LVSEd及LAd均低于择期手术组,差异具有统计学意义(P0.05);手术后,两组患者mMPG及mPAP均低于手术前,且急诊手术组患者mMPG及mPAP均低于择期手术组,差异具有统计学意义(P0.05);急诊手术组患者术后6个月心衰再住院率(2.04%)低于择期手术组(6.25%),差异具有统计学意义(P0.05)。结论:手术时机的选择对于行经皮冠脉介入手术的急性心肌梗死患者具有重要意义。与择期手术效果相比,急诊手术能够更好地改善患者的心功能及左室重构,减少心衰再住院率,值得在临床推广应用。     

Myocardial Infarction: A Five-Year Follow-up of Patients

Patients with acute myocardial infarction (2,020) admitted to coronary care units (CCU) in Utah were studied for five years. Of these, 1,641 (81.4 percent) survived to leave the hospital. The male to female ratio was 3.5:1. At four months, one year and yearly thereafter from the date of admission to CCU, patients were mailed follow-up questionnaires. Cause of death was obtained from autopsy reports and death certificates. Patients were grouped yearly by the number of cardiac symptoms reported. Of patients discharged whose cases were followed, 925 (61.9 percent) were alive after five years. Reinfarction was the major cause of death in the hospital; however, during follow-up only 36.8 percent of deaths were attributable to myocardial infarction. At follow-up after a year, fewer cardiac symptoms were reported by patients who survived to the fifth year of follow-up than by patients who did not. Women were older and showed a higher death rate during follow-up. Increasing age was found to be a determining factor in long-term mortality after acute myocardial infarction.     

Oxidized Low-Density Lipoprotein and C-Reactive Protein Have Combined Utility for Better Predicting Prognosis After Acute Coronary Syndrome

It has been shown that the elevated concentrations of oxidized low-density lipoprotein (Ox-LDL) or high-sensitivity C-reactive protein (hs-CRP) are predictive of future cardiovascular events for acute coronary syndrome (ACS) patients. But, the combined value of Ox-LDL and hs-CRP for predicting cardiovascular events is still unknown. Serum concentrations of Ox-LDL, hs-CRP, and cTnT were measured in a prospective cohort of 425 selective ACS patients followed 3–5 years for the occurrence of acute myocardial infarction (AMI) or death (AMI/death). Among 425 enrolled patients, 124 patients demonstrated AMI/death. Baseline levels of Ox-LDL, hs-CRP, and cTnT were significantly higher in AMI/death group than the event-free survival group. Kaplan–Meier survival analyses supported that elevations in Ox-LDL or hs-CRP predicted increased cardiovascular events risks. However, the strongest risk prediction was achieved by assessing Ox-LDL and hs-CRP together. Patients with high levels of Ox-LDL and hs-CRP were more likely to experience AMI or death than those with either Ox-LDL or hs-CRP elevated. Receiver-operating characteristic curves showed that Ox-LDL and hs-CRP have higher sensitivity and specificity than those of cTnT for predicting AMI or death. This was reflected by the AUC values for Ox-LDL, hs-CRP, and cTnT, which were 0.891, 0.834, and 0.626, respectively. The combined use of Ox-LDL and hs-CRP may improve prognosis after ACS with high-sensitivity and specificity.     

Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis

Background

Multivessel disease is common in acute coronary syndrome patients. However, if multivessel percutaneous coronary intervention is superior to culprit-vessel angioplasty has not been systematically addressed.

Methods

A metaanalysis was conducted including studies that compared multivessel angioplasty with culprit-vessel angioplasty among non-ST elevation ACS patients. Since all studies were observational adjusted estimates of effects were used. Pooled estimates of effects were computed using the generic inverse of variance with a random effects model.

Results

Twelve studies were included (n = 117,685). Median age was 64.1 years, most patients were male, 29.3% were diabetic and 36,9% had previous myocardial infarction. Median follow-up was 12 months. There were no significant differences in mortality risk (HR 0.79; 95% CI 0.58 to 1.09; I² 67.9%), with moderate inconsistency. Also, there were no significant differences in the risk of death or MI (HR 0.90; 95% CI 0.69 to 1.17; I² 62.3%), revascularization (HR 0.76; 95% CI 0.55 to 1.05; I² 49.9%) or in the combined incidence of death, myocardial infarction or revascularization (HR 0.83; 95% CI 0.66 to 1.03; I² 70.8%). All analyses exhibited a moderate degree of inconsistency. Subgroup analyses by design reduced the inconsistency of the analyses on death or myocardial infarction, revascularization and death, myocardial infarction or revascularization. There was evidence of publication bias (Egger’s test p = 0.097).

Conclusion

Routine multivessel angioplasty in non-ST elevation acute coronary syndrome patients with multivessel disease was not superior to culprit-vessel angioplasty. Randomized controlled trials comparing safety and effectiveness of both strategies in this setting are needed.     

NT-proBNP、BNP及hs-CRP在老年急性非ST段抬高型心肌梗死患者血浆中的表达及临床意义

目的:探讨N末端前体脑钠肽(NT-proBNP)、脑钠肽(BNP)及超敏C-反应蛋白(hs-CRP)在老年急性非ST段抬高型心肌梗死患者血浆中的表达及临床意义。方法:选择2015年2月～2018年7月在我院进行诊治的老年急性非ST段抬高型心肌梗死患者200例为观察组,选择同期在我院进行诊治的非冠脉综合征患者100例为对照组。入院后次日检测所有患者的血浆中的NT-proBNP、BNP及hs-CRP等指标的水平,并对比两组患者以及观察组中不同血管病变支数患者上述指标水平。两组患者均随访6个月,观察心血管不良事件的发生率。结果:观察组患者的NT-proBNP、BNP及hs-CRP水平均显著高于对照组,组间比较差异有统计学意义(P0.05)。观察组内单支血管病变、双支血管病变、三支血管病变患者间NT-proBNP、BNP及hs-CRP水平比较差异有统计学意义(P0.05),各项指标水平随着血管病变支数增加而升高(P0.05)。观察组在出院后为期6个月随访期间心血管不良事件发生率为16.50%,高于对照组心血管不良事件发生率为6.00%,组间比较差异有统计学意义(P0.05)。患者冠脉血管病变支数与血浆NT-proBNP、BNP及hs-CRP水平间呈正相关(P0.05)。结论:血浆NT-proBNP、BNP及hs-CRP水平在老年急性非ST段抬高型心肌梗死患者中显著升高,且随着患者血管病变程度的增加而升高,对患者预后心血管不良事件判断有较好的预测作用。     

Glucose challenge increases circulating progenitor cells in Asian Indian male subjects with normal glucose tolerance which is compromised in subjects with pre-diabetes: A pilot study

Background

Patients with acute myocardial infarction and newly detected abnormal glucose regulation have been shown to have a less favourable prognosis compared to patients with normal glucose regulation. The importance and timing of oral glucose tolerance testing (OGTT) in patients with acute myocardial infarction without known diabetes is uncertain. The aim of the present study was to evaluate the impact of abnormal glucose regulation classified by an OGTT in-hospital and at three-month follow-up on clinical outcome in patients with acute ST elevation myocardial infarction (STEMI) without known diabetes.

Methods

Patients (n = 224, age 58 years) with a primary percutanous coronary intervention (PCI) treated STEMI were followed for clinical events (all-cause mortality, non-fatal myocardial re-infarction, recurrent ischemia causing hospital admission, and stroke). The patients were classified by a standardised 75 g OGTT at two time points, first, at a median time of 16.5 hours after hospital admission, then at three-month follow-up. Based on the OGTT results, the patients were categorised according to the WHO criteria and the term abnormal glucose regulation was defined as the sum of impaired fasting glucose, impaired glucose tolerance and type 2-diabetes.

Results

The number of patients diagnosed with abnormal glucose regulation in-hospital and at three-month was 105 (47%) and 50 (25%), respectively. During the follow up time of (median) 33 (27, 39) months, 58 (25.9%) patients experienced a new clinical event. There were six deaths, 15 non-fatal re-infarction, 33 recurrent ischemia, and four strokes. Kaplan-Meier analysis of survival free of composite end-points showed similar results in patients with abnormal and normal glucose regulation, both when classified in-hospital (p = 0.4) and re-classified three months later (p = 0.3).

Conclusions

Patients with a primary PCI treated STEMI, without previously known diabetes, appear to have an excellent long-term prognosis, independent of the glucometabolic state classified by an OGTT in-hospital or at three-month follow-up.

Trial registration

The trial is registered at http://www.clinicaltrials.gov, NCT00926133.